Immunic Inc (NASDAQ:IMUX, FRA:10VA) said it will participate in two April conferences.
At the Neuroimmunology Drug Development Summit (Apr. 14–16, Boston), CSO Hella Kohlhof will present on lead asset vidofludimus calcium (IMU-838), highlighting its neuroprotective and anti-inflammatory potential for multiple sclerosis. The presentation will be available on the company’s website.
Immunic will also attend the American Academy of Neurology Annual Meeting (Apr. 18–22, Chicago), with its team present at booth #3830.